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Summary
Background Neonates who are in pain or are stressed during care in the intensive care unit (ICU) are often given sedation 
or analgesia. We investigated the current use of sedation or analgesia in neonatal ICUs (NICUs) in European countries.
Methods EUROPAIN (EUROpean Pain Audit In Neonates) was a prospective cohort study of the management of 
sedation and analgesia in patients in NICUs. All neonates admitted to NICUs during 1 month were included in this 
study. Data on demographics, methods of respiration, use of continuous or intermittent sedation, analgesia, or 
neuromuscular blockers, pain assessments, and drug withdrawal syndromes were gathered during the ﬁ rst 28 days of 
admission to NICUs. Multivariable linear regression models and propensity scores were used to assess the association 
between duration of tracheal ventilation (TV) and exposure to opioids, sedatives-hypnotics, or general anaesthetics in 
neonates (O-SH-GA). This study is registered with ClinicalTrials.gov, number NCT01694745.
Findings From Oct 1, 2012, to June 30, 2013, 6680 neonates were enrolled in 243 NICUs in 18 European countries. 
Mean gestational age of these neonates was 35∙0 weeks (SD 4∙6) and birthweight was 2384 g (1007). 2142 (32%) 
neonates were given TV, 1496 (22%) non-invasive ventilation (NIV), and 3042 (46%) were kept on spontaneous 
ventilation (SV). 1746 (82%), 266 (18%), and 282 (9%) neonates in the TV, NIV, and SV groups, respectively, were given 
sedation or analgesia as a continuous infusion, intermittent doses, or both (p<0∙0001). In the participating NICUs, the 
median use of sedation or analgesia was 89∙3% (70∙0–100) for neonates in the TV group. Opioids were given to 
1764 (26%) of 6680 neonates and to 1589 (74%) of 2142 neonates in the TV group. Midazolam was given to 576 (9%) of 
6680 neonates and 536 (25%) neonates of 2142 neonates in the TV group. 542 (25%) neonates in the TV group were 
given neuromuscular blockers, which were administered as continuous infusions to 146 (7%) of these neonates. Pain 
assessments were recorded in 1250 (58%) of 2138, 672 (45%) of 1493, and 916 (30%) of 3017 neonates in the TV, NIV, 
and SV groups, respectively (p<0∙0001). In the univariate analysis, neonates given O-SH-GA in the TV group needed a 
longer duration of TV than did those who were not given O-SH-GA (mean 136∙2 h [SD 173∙1] vs 39∙8 h [94∙7] h; 
p<0∙0001). Multivariable and propensity score analyses conﬁ rmed this association (p<0∙0001).
Interpretation Wide variations in sedation and analgesia practices occur between NICUs and countries. Widespread 
use of O-SH-GA in intubated neonates might prolong their need for mechanical ventilation, but further research is 
needed to investigate the therapeutic and adverse eﬀ ects of O-SH-GA in neonates, and to develop new and safe 
approaches for sedation and analgesia.
Funding European Community’s Seventh Framework Programme.
Introduction
According to compelling evidence, all newborn babies, 
including those born preterm, respond to pain.1,2 
Recurring pain in neonates leads to poor cognition3 and 
motor function,4 impaired brain development,5,6 and 
altered pain responses.7 Since care in the neonatal 
intensive care unit (NICU) involves invasive and non-
invasive procedures, mechanical ventilation, and medical 
or surgical disorders that can cause pain or stress, 
widespread practices include the administration of 
sedation and analgesia to patients in the NICU.8 Recent 
concerns about the neurotoxic eﬀ ects of analgesics 
(including opioids), sedatives, and anaesthetics on the 
developing brain9 have triggered a debate about their 
potential neuroprotective and neurotoxic eﬀ ects in 
newborn babies.10 Very little is known, however, about 
international sedation and analgesia practices at the 
bedside. Research into the comparative eﬀ ectiveness of 
these practices and the factors associated with them will 
enable the deﬁ nition of best practices and future clinical 
trials.
We aimed to describe the current use of sedation, 
analgesia, and neuromuscular blockers at the bedside in 
NICUs in European countries and to describe the factors 
associated with sedation or analgesia use.
Methods
Study design and participants
EUROPAIN (EUROpean Pain Audit In Neonates) was a 
prospective cohort study of the management of pain and 
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stress with sedation and analgesia in patients in the 
NICU, without interfering with routine clinical practices. 
The background, objectives, and methods of the study in 
diﬀ erent languages, with detailed videos on how to 
complete online questionnaires, and all documents and 
daily progress reports were accessible through the survey 
website. All material and documents used or obtained for 
this study, such as protocols in English and other national 
languages, posters, PowerPoint presentations for local 
teams, announcements, and ethics committee approvals, 
were available online. Website links connected authorised 
users to a secure server hosting the application Voozanoo 
(version 3) for data entry into standardised questionnaires 
in the national language.
By contacting national neonatal societies and existing 
networks, we identiﬁ ed a volunteer neonatologist or 
neonatal nurse in each country (Austria, Belgium, 
Cyprus, Estonia, Finland, France, Germany, Greece, Italy, 
Lithuania, Malta, the Netherlands, Norway, Poland, 
Portugal, Spain, Sweden, and the UK) to be the national 
principal investigator. The national principal investigator 
for each country invited the chiefs of all existing NICUs to 
participate in this study. The letter of invitation was 
standardised and written in English for all countries and 
had a web-link to the online study questionnaires. The 
national principal investigators added a personal 
explanation in their national language to this letter. Level 
3 units were globally deﬁ ned as units that are able to 
provide care for critically ill neonates of all gestational 
ages and weights and that provide mechanical ventilation 
support for as long as needed. Level 3 NICUs that initiated 
and did the complete period of tracheal ventilation (TV) 
were eligible, whereas NICUs transferring ventilated 
newborn babies to other units were not eligible. To avoid 
distortion of the appraisal of the real management of 
neonates in intensive care units (ICUs), paediatric 
intensive care units (PICUs) that cared for neonates also 
participated in the study. All centres that agreed to 
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Research in context
Evidence before this study
We did a MEDLINE search using the words “pain”, “newborn”, 
“sedation”, and “analgesia” in diﬀ erent combinations without 
any date restrictions, and a cross-reference search of the articles 
we found yielded only three studies that brieﬂ y included, among 
other objectives, the assessment of general sedation or analgesia 
practices in the neonatal intensive care unit (NICU). Two were 
declarative national surveys and one was a cross-sectional survey. 
In Swedish NICUs, pharmacological analgesia was used during 
mechanical ventilation but no information was reported about 
the type or frequency of drugs used; 33 (37%) of 90 Italian NICUs 
reported routine use of opioid drugs for mechanical ventilation. 
The results of a survey done in 1993–94 in 14 Canadian NICUs 
showed that 51 (21%) of 239 neonates received analgesia or 
anaesthesia, or both, during a 1 week study period. Most of the 
other excluded epidemiological studies assessed procedural pain 
management or particular situations (postoperative, mechanical 
ventilation during chronic lung disease, or necrotising 
enterocolitis) in the NICU. For the clinical eﬀ ects of the use of 
opioid drugs, sedatives-hypnotics, or general anaesthetics in 
neonates who were tracheally ventilated, a search of the 
Cochrane database yielded two systematic reviews on the use of 
opioid drugs and the use of midazolam. One systematic review 
was of ten studies that reported the duration of tracheal 
ventilation during treatment with opioid drugs; a meta-analysis 
of six studies showed no signiﬁ cant eﬀ ect of opioid 
administration on the duration of tracheal ventilation. The other 
systematic review was of three studies on intravenous infusion 
of midazolam for sedation of infants in the NICU to ascertain 
whether midazolam was an eﬀ ective sedative and to assess 
clinically signiﬁ cant short-term and long-term adverse eﬀ ects. 
A signiﬁ cantly longer stay in NICU was noted in the midazolam 
group than in the placebo group. No data for the duration of 
tracheal ventilation were reported.
Added value of this study
To our knowledge, this is the ﬁ rst prospective, multicentre, 
international study reporting 24 h bedside practices of 
sedation and analgesia in European NICUs. Our study cohort 
was representative of NICU populations in Europe and other 
developed countries with the participation of 18 countries, 
standardisation of data gathering, and more than 90% 
inclusion rates in 16 of 18 countries. The inclusion of 
2142 neonates who were tracheally ventilated and the wide 
range of practices enabled a robust identiﬁ cation of factors 
associated with the use of sedation or analgesia in these 
infants and a detailed analysis of the association between the 
use of opioids, sedatives-hypnotics, or general anaesthetics 
and the duration of tracheal ventilation. Unlike the results of 
previous studies, treatment with opioids, sedatives-hypnotics, 
or general anaesthetics was associated with prolonged 
ventilation in neonates who were tracheally ventilated. We 
noted that 34% of NICU admissions and 82% of neonates who 
were tracheally ventilated received some sedation or analgesia 
with wide variations in practices between diﬀ erent NICUs and 
diﬀ erent countries. 74% of neonates who were tracheally 
ventilated received opioids and a quarter received midazolam.
Implications of all available evidence
The wide variations in sedation and analgesia practices 
between different NICUs and different countries in this 
study and the association of the use of opioids, 
sedatives-hypnotics, or general anaesthetics with increased 
durations of tracheal ventilation emphasise the need to 
develop international guidelines for judicious use of 
sedation or analgesia in the NICU, to investigate the 
therapeutic and adverse effects of these drugs in neonates, 
and to develop new safe approaches for sedation or 
analgesia in neonates in intensive care.
For the EUROPAIN survey see 
www.europainsurvey.eu
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participate identiﬁ ed a nurse and a physician coordinator, 
and a data quality manager. Nurse and physician 
coordinators in each unit provided information to the 
principal investigators about general statistics and local 
sedation and analgesia protocols for neonates. The 
national principal investigator provided data to the 
principal investigators about national guidelines for the 
management of pain in neonates.
Study protocols and data gathering were ﬁ rst approved 
in France by the regulatory organisations for the 
Protection of Human Subjects and data, and health 
research data management, and then approved by similar 
committees in each country and, if necessary, at each 
participating site. Information sheets were given to 
parents to explain that the gathered data would be 
anonymous and they could opt out of their child’s 
participation at any time.
Data gathering
All neonates up to 44 weeks of post-conception age who 
were admitted to the NICU during enrolment were 
eligible for inclusion in the study; neonates already in 
the NICU at the start of enrolment were not included in 
the study. We gathered data prospectively for each 
neonate during the ﬁ rst 28 days of stay in the hospital, or 
until death, discharge, or transfer to another hospital on 
the demographics, methods of respiration, use of 
continuous or intermittent (bolus) sedation, analgesia, 
or neuro muscular blockers, pain assessments with any 
validated scale (a list of scales was available on the data 
gathering form and NICUs could add any other scale 
they used), and speciﬁ c practices to treat or prevent drug 
withdrawal syndromes. Data were gathered for the types 
of ventilation used or study medications given 
irrespective of the reasons for their use in the NICU. We 
did not gather data on medications given before 
admission to the NICU. We did not obtain data on daily 
sedation interruptions or vacations, use of sedation 
scales, or the type or number of invasive or non-invasive 
procedures. The exact durations of continuous infusion 
of sedatives or analgesics were registered; for bolus 
administration, we recorded the number of daily doses. 
Neonates were classiﬁ ed as being in the sedation or 
analgesia group if they received at least one dose of 
medication. NICUs recruited patients over 1 month, 
which was judged to be suﬃ  cient to study the practices 
of all rotating personnel while minimising temporal 
changes in clinical practices. Not all the NICUs included 
patients during the same period. Recruitment periods 
were determined by the completion of regulatory 
compliances of NICUs, preferences, and capability of 
the monitoring team in Paris, France, to follow the 
inclusion of patients. This monitoring team aimed at 
having no more than 40 NICUs recruiting patients at the 
same time because the team followed and checked 
inclusion of every patient. Data were gathered on 
standardised paper questionnaires and then entered 
online, or were entered directly online. Each NICU also 
kept a log book of all neonates admitted during the 
study.
A centralised monitoring team in Paris monitored the 
completeness of data entered into the study database and 
identiﬁ ed potential errors by checking the coherence of 
entered data. Missing or potentially incongruous data 
were reported to unit coordinators and double checked 
locally. After the inclusion of all the patients, the 
monitoring team randomly selected 10% of patients (a 
minimum of ﬁ ve patients) and the local data quality 
manager double checked all the data for these patients. If 
1% or more errors were detected, the data for another 
10% of patients were double checked; if error rates of 1% 
persisted, all data entries from that NICU were double 
checked.
Statistical analysis
We anticipated the participation of at least 15 countries and 
planned to make comparisons between all countries. We 
used a χ² power analysis to calculate the sample size. We 
expected small diﬀ erences in sedation or analgesia 
practices between countries and thus used an eﬀ ect size 
(W) of 0∙1 for calculations. By use of NCSS-PASS (version 
2008), a sample size of 2303 neonates would achieve 90% 
power to detect an eﬀ ect size of 0∙1 with 14 degrees of 
freedom (15 centres), using a χ² test with an α of 0∙05 (see 
appendix for further details).
We used SPSS (version 17.0) for the analysis of 
descriptive data and Stata (version 13.0) for multivariable 
models and propensity score procedures. To elucidate 
factors associated with sedation or analgesia use, clinical 
factors correlated with the use of sedation or analgesia 
(p<0∙2) in the univariate analysis were included in 
logistic regression models, with stepwise backward 
elimination of non-signiﬁ cant covariates. Independent 
variables were country, sex, gestational age, type of 
respiratory support, severity of illness (Clinical Risk 
Index for Babies [CRIB] score: consists of six items 
measured in the ﬁ rst 12 h after birth and ranges from 
0 to 23, with higher scores indicating higher clinical 
risk), age at admission, intrauterine growth retardation, 
respiratory distress syndrome, 1 min and 5 min Apgar 
scores, intubation at NICU admission, and assessment 
with a pain scale. Because data were clustered, p values 
and 95% CIs were adjusted with a robust sandwich 
estimator. Results of regression analyses are presented as 
odds ratio (OR) with two-sided 95% CIs. An internal 
validation of the logistic model was done with a bootstrap 
approach with 1000 samples.
We assessed the association between exposure to 
opioids, sedatives-hypnotics, or general anaesthetics 
(O-SH-GA) and duration of tracheal ventilation in infants 
because of concern about the prolongation of invasive 
ventilation. All covariates associated (p<0∙20) with 
duration of tracheal ventilation in univariate analyses 
were included in multivariable linear regression models 
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Mean (SD) 35·0 (4·6) 32·7 (5·2) 33·8 (3·8) 37·3 (3·1) <0·0001
Median (IQR) 35·6 (32·0–39·0) 32·1 (28·1–37·4) 33·6 (31·0–36·6) 37·9 (35·0–39·9) <0·0001
24–29 1049 (16%) 779 (36%) 214 (14%) 56 (2%) <0·0001†
30–32 1015 (15%) 360 (17%) 454 (30%) 201 (7%)
33–36 1864 (28%) 389 (18%) 486 (32%) 989 (33%)
37–42 2750 (41%) 613 (29%) 342 (23%) 1795 (59%)
Birthweight (g)
Mean (SD) 2384 (1007) 1948 (1035) 2132 (891) 2816 (855) <0·0001
Median (IQR) 2370 (1570–3170) 1740 (1000–2800) 1970 (1440–2720) 2870 (2140–3445) <0·0001
Sex, male 3775 (57%) 1260 (59%) 842 (56%) 1673 (55%) 0·10
Born in same hospital as NICU 5367 (80%) 1460 (68%) 1307 (87%) 2600 (85%) <0·0001
Type of delivery <0·0001
Vaginal 3074 (46%) 879 (41%) 571 (38%) 1624 (53%)
Caesarean 3586 (54%) 1249 (59%) 923 (62%) 1414 (47%)
Age at admission (h)
Mean (SD) 65·2 (244·3) 84·1 (294·0) 47·5 (224·2) 60·6 (212·3) <0·0001
Median (IQR) 1·0 (0·3–12·1) 0·8 (0·3–8·3) 0·5 (0·2–1·7) 3·0 (0·4–26·8) <0·0001
CRIB score
Mean (SD) 1·4 (2·5) 3·3 (3·5) 0·8 (1·5) 0·4 (1·0) <0·0001
Median (IQR) 0 (0–2) 2 (1–5) 0 (0–1) 0 (0–0) <0·0001
Apgar score at 5 min
Mean (SD) 8·4 (1·9) 7·4 (2·4) 8·5 (1·4) 9·0 (1·3) <0·0001
Median (IQR) 9 (8–10) 8 (6–9) 9 (8–10) 9 (9–10) <0·0001
Already intubated at admission 1376 (21%)‡ 1376 (64%) NA NA NA
Died during study 211 (3%) 201 (9%) 3 (<1%) 7 (<1%) <0·0001
Hospital admission (days)§
Mean (SD) 11·9 (9·7) 15·7 (10·2) 14·2 (9·9) 8·0 (7·4) <0·0001
Median (IQR) 8 (3–20) 14 (6–28) 11 (5–26) 5 (3–11) <0·0001
Duration of ventilation (h)
Tracheal ventilation¶
Mean (SD) NA 115 (164) NA NA NA
Median (IQR) NA 49 (15–130) NA NA NA
Non-invasive ventilation¶
Mean (SD) NA 178 (197) 92 (148) NA NA
Median (IQR) NA 84 (24–294) 34 (13–97) NA NA
Spontaneous ventilation¶
Mean (SD) NA 207 (192) 249 (213) 169 (179) NA
Median (IQR) NA 139 (45–340) 173 (55–437) 103 (39–233) NA
Sedatives or analgesics
Method of administration
Any form|| 2294 (34%) 1746 (82%) 266 (18%) 282 (9%) <0·0001**
Continuous only 309 (5%) 294 (14%) 5 (<1%) 10 (<1%)
Bolus only 937 (14%) 452 (21%) 247 (17%) 238 (8%)
Continuous and bolus 1048 (16%) 1000 (47%) 14 (1%) 34 (1%)
Type††
Opioid analgesics 1764 (26%)‡‡ 1589 (74%) 87 (6%) 88 (3%) <0·0001
Sedatives-hypnotics 786 (12%) 690 (32%) 43 (3%) 53 (2%) <0·0001
Midazolam 576 (9%) 536 (25%) 16 (1%) 24 (1%)
Barbiturates 96 (1%) 69 (3%) 8 (1%) 19 (1%)
(Table 1 continues on next page)
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to assess this association. Because infants were not 
randomly assigned to receive O-SH-GA, we used 
propensity scores to reduce the eﬀ ect of treatment-
selection bias and potential confounders in the study. 
The propensity score for an individual is the probability 
of being treated conditionally based on the individual’s 
covariate values.11 We calculated the propensity score on 
the basis of the covariates used in the logistic regression 
model predicting the use of O-SH-GA. Infants treated 
and not treated with these drugs but with a similar 
propensity for treatment with O-SH-GA were matched. 
The matching was done, after the random ordering of 
infants, using the psmatch2 algorithm12 in Stata (version 
13.0) with one-to-one nearest neighbour matching 
without replacement and with maximum calliper 
distance of 0∙125 times the propensity score SD. The 
covariate imbalance and its correction between the 
groups treated and not treated with O-SH-GA were 
measured as the absolute standardised diﬀ erences for 
the comparison of the groups. Standardised diﬀ erences 
of up to 10% were deemed inconsequential.13 Using 
matched pairs, we compared the duration of TV in 
infants treated or not treated with O-SH-GA. In all the 
neonates in the TV group, use of two other techniques 
based on the propensity score, stratiﬁ cation, and 
regression adjustment, conﬁ rmed the analyses done in 
matched pairs.11 Stratiﬁ cation based on propensity score 
quintiles divided the TV group into ﬁ ve strata. Within 
each stratum, infants treated or not treated with 
O-SH-GA were compared. Previous research showed 
that this technique removes up to 90% bias caused by 
confounding variables.11 To further adjust for 
confounders, two multivariable linear regression models 
predicting duration of TV were constructed, one 
including only the propensity score and O-SH-GA 
treatment status as independent variables and another 
including these variables plus all variables signiﬁ cantly 
associated with the duration of TV in univariate analyses. 
Because the rate of mortality can have an eﬀ ect on the 
duration of TV, we used the number of ventilator-
free days as a secondary endpoint to estimate the eﬀ ect of 
the use of O-SH-GA. This outcome is largely used in 
reports about ICUs.14 Ventilator-free days were deﬁ ned as 
the number of calendar days from the time of tracheal 
extubation to day 28 after NICU admission. If a neonate 
was reintubated and subsequently extubated 
before day 28, ventilator-free days were counted from the 
end of the last period of tracheal intubation. If a neonate 
was receiving TV on day 28 or died before day 28, 
ventilator-free days were zero.15 For neonates discharged 
before day 28 of admission, ventilator-free days were zero 
if the neonate was still intubated at discharge (transfer) 
and ventilator-free days were counted from the time of 
tracheal extubation to day 28 after NICU admission if the 
neonate was already extubated at discharge. Ventilator-
free days were compared with the paired-sample 
Wilcoxon rank test. Two-tailed p values of 0∙05 or less 
were deemed signiﬁ cant.













(Continued from previous page)
Other 195 (3%) 157 (7%) 20 (1%) 18 (1%)
General anaesthetics 199 (3%) 178 (8%) 13 (<1%) 8 (<1%) <0·0001
Ketamine 136 (2%) 120 (6%) 9 (<1%) 7 (<1%)
Propofol 65 (1%) 59 (3%) 5 (<1%) 1 (<1%)
Inhalational anaesthetics 3 (<1%) 3 (<1%) 0 (0%) 0 (0%)
Paracetamol 904 (14%) 530 (25%) 172 (11%) 202 (7%) <0·0001
Ibuprofen 16 (<1%) 14 (1%) 1 (<1%) 1 (<1%) <0·0001
Local anaesthetics 26 (<1%) 21 (1%) 2 (<1%) 3 (<1%) <0·0001
Other drugs 16 (<1%) 11 (1%) 0 (0%) 5 (<1%) 0·0038
Neuromuscular blockers 542 (8%) 542 (25%) 0 (0%) 0 (0%) <0·0001
Pain assessment with a scale§§ 2838 (42%) 1250 (58%) 672 (45%) 916 (30%) <0·0001
Withdrawal syndrome diagnosed 94 (1%) 69 (3%) 4 (<1%) 21 (1%) <0·0001
Some variables had missing values. NICU=neonatal intensive care unit. NA=not applicable. CRIB=Clinical Risk Index for Babies. *Comparisons of the three types of ventilation 
were done with χ² (Fisher’s exact test when required), ANOVA, or Kruskal-Wallis test. †χ² for distributions in all strata of gestational ages within the three ventilation groups. 
‡26 infants were intubated immediately on arrival in the NICU and thus were included in this group. §Data gathering was stopped on day 28 of hospital stay; 1043 (16%) of 
6679 neonates were hospitalised for longer than 28 days. ¶For the tracheal ventilation group, time on non-invasive ventilation or spontaneous ventilation refers to 
non-invasive ventilation or spontaneous ventilation before tracheal intubation or after extubation; and for the non-invasive ventilation group, time on spontaneous 
ventilation refers to the periods of spontaneous ventilation before or after non-invasive ventilation use. ||Continuous or bolus, or both. **χ² for comparisons of use of any 
form of sedation analgesia in the three ventilation groups. ††Some neonates were given more than one type of analgesic or sedative. ‡‡Of 1764 neonates, 1707 (97%) were 
given one or more of the following drugs: morphine (n=1016), fentanyl (n=694), or sufentanil (n=227). §§Information was available for 2138 neonates in the tracheal 
ventilation group, 1493 in the non-invasive ventilation group, and 3017 in the spontaneous ventilation group.
Table 1: Baseline characteristics of 6680 neonates and use of sedation and analgesia by ventilation group in the NICUs
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Mean (SD) 29·4 (2·5) 28·4 (2·5) 30·4 (1·9) 30·9 (2·1) <0·0001
Median (IQR) 29·9 (27·4–31·6) 28·4 (26·4–30·4) 30·9 (29·4–32·0) 31·6 (30·0–32·3) <0·0001
Birthweight (g)
Mean (SD) 1269 (436) 1131 (417) 1419 (397) 1490 (394) <0·0001
Median (IQR) 1230 (920–1580) 1045 (801–1395) 1411 (1116–1718) 1500 (1255–1755) <0·0001
Sex, male 1154 (56%) 674 (59%) 352 (53%) 128 (50%) 0·009
Born in same hospital as NICU 1681 (81%) 909 (80%) 590 (88%) 182 (71%) <0·0001
Type of delivery 0·015
Vaginal 708 (34%) 401 (35%) 204 (31%) 103 (40%)
Caesarean 1352 (66%) 735 (65%) 463 (69%) 154 (60%)
Age at admission (h)
Mean (SD) 125·6 (395·1) 110·9 (373·1) 79·2 (312·4) 311·5 (586·4) <0·0001
Median (IQR) 0·5 (0·3–1·8) 0·5 (0·3–2·0) 0·4 (0·2–0·9) 0·8 (0·3–273·5) <0·0001
CRIB score
Mean (SD) 2·5 (3·3) 3·8 (3·7) 1·1 (1·7) 1·0 (1·8) <0·0001
Median (IQR) 1 (0–4) 2 (1–6) 1 (0–1) 0 (0–1) <0·0001
Apgar score at 5 min
Mean (SD) 8·0 (1·9) 7·4 (2·1) 8·6 (1·3) 9·0 (1·2) <0·0001
Median (IQR) 8 (7–9) 8 (6–9) 9 (8–9) 9 (9–10) <0·0001
Already intubated at admission 811 (39%)† 811 (71%) NA NA NA
Died during study 139 (7%) 139 (12%) 0 (0%) 0 (0%) <0·0001
Hospital admission (days)‡
Mean (SD) 19·4 (9·8) 19·8 (9·9) 19·4 (9·6) 17·3 (9·4) 0·001
Median (IQR) 25 (10–28) 28 (10–28) 25 (9–28) 18 (8–28) <0·0001
Duration of ventilation (h)
Tracheal ventilation§
Mean (SD) NA 147 (194) NA NA NA
Median (IQR) NA 58 (18–182) NA NA NA
Non-invasive ventilation§
Mean (SD) NA 243 (208) 155 (192) NA NA
Median (IQR) NA 181 (53–429) 70 (25–188) NA NA
Spontaneous ventilation§
Mean (SD) NA 269 (215) 341 (227) 394 (227) NA
Median (IQR) NA 221 (67–472) 359 (110–565) 417 (171–649) NA
Sedatives or analgesics
Method of administration
Any form¶ 1031 (50%) 881 (77%) 124 (19%) 26 (10%) <0·0001||
Continuous only 155 (8%) 154 (14%) 1 (<1%) 0 (0%)
Bolus only 420 (20%) 279 (24%) 119 (18%) 22 (9%)
Continuous and bolus 456 (22%) 448 (39%) 4 (1%) 4 (2%)
Type**
Opioid analgesics 851 (41%)†† 796 (70%) 49 (7%) 6 (2%) <0·0001
Sedatives-hypnotics 272 (13%) 255 (22%) 15 (2%) 2 (1%) <0·0001
Midazolam 197 (10%) 190 (17%) 5 (1%) 2 (1%)
Barbiturates 16 (1%) 12 (1%) 4 (1%) 0 (0%)
Other 63 (3%) 58 (5%) 5 (1%) 0 (0%)
General anaesthetics 82 (4%) 72 (6%) 10 (1%) 0 (0%) <0·0001
Ketamine 42 (2%) 35 (3%) 7 (1%) 0 (0%)
Propofol 42 (2%) 38 (3%) 4 (1%) 0 (0%)
Inhalational anaesthetics 2 (<1%) 2 (<1%) 0 (0%) 0 (0%)
(Table 2 continues on next page)
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Role of the funding source
The funder of the study had no role in the design of the 
study, data gathering, analysis, or interpretation, writing 
of the report, or in the decision to submit the report for 
publication. The corresponding author had full access to 
all the data in the study, takes responsibility for the 
integrity of the data and the accuracy of the data analyses, 
and had ﬁ nal responsibility for the decision to submit for 
publication.
Results
From Oct 1, 2012, to June 30, 2013, 243 NICUs in 
18 European countries enrolled 6680 neonates 
(appendix). The appendix shows, for each country, how 
representative participating NICUs were of all eligible 
NICUs. Six countries (33%) had national guidelines 
and 182 NICUs (75%) reported local protocols for 
neonatal sedation or analgesia. The mean gestational 
age of the neonates was 35∙0 weeks (SD 4∙6) and 
the birthweight was 2384 g (1007) (table 1). The 
mean period of participation in the study was 
11∙9 calendar days (9∙7; table 1) and the neonates were 
observed for a total of 79 185 patient days.
Patients were classiﬁ ed into three groups depending 
on the highest level of ventilation needed during the 
study: TV (n=2142), non-invasive ventilation (NIV; 
n=1496), and spontaneous ventilation (SV; n=3042). 
During the study, 99 (5%) of 2142 neonates in the TV 
group needed surgery (diﬀ erent from the invasive 
procedures undertaken at the bedside), which was 
performed by a consultant specialist. Neonates in the TV 
group had lower gestational age, birthweight, rates of 
birth in the study hospital, and Apgar scores, and higher 
age at admission and disease severity scores (CRIB) than 
did those in the NIV and SV groups (table 1). In the TV 
group, 64% of neonates of all gestational ages and 71% of 
those younger than 33 weeks were already intubated at 
NICU admission (tables 1 and 2).
Of the 6680 neonates enrolled, 2294 (34%) were 
administered, at least once, sedation or analgesia by 
continuous infusion or intermittent (bolus) doses or 
both: 82% in the TV group, 18% in the NIV group, and 
9% in the SV group (p<0∙0001; table 1). The median use 
of sedation or analgesia by the 243 NICUs for all neonates 
and for neonates in the TV group were 33∙3% 
(IQR 18∙5–56∙5) and 89∙3% (70∙0–100), respectively.
Opioids included mainly morphine (given to 923 [43%] 
of 2142, 37 [2%] of 1496, and 56 [2%] of 3042 neonates in 
the TV, NIV, and SV groups, respectively), fentanyl (629 
[29%], 41 [3%], and 24 [1%]), and sufentanil (220 [10%], 
two [<1%], and ﬁ ve [<1%]); sedatives-hypnotics included 
mainly midazolam (536 [25%], 16 [1%], and 24 [1%]), 
chloral hydrate (83 [4%], 17 [1%], and 13 [<1%]), and 
phenobarbital (54 [3%], seven [<1%], and 19 [1%]); general 
anaesthetics included mainly ketamine (120 [6%], nine 
[1%], and seven [<1%]) and propofol (59 [3%], ﬁ ve [<1%], 
and one [<1%]; propofol was always administered as a 
bolus). Opioids were the most commonly administered 
medi cation to neonates followed by sedative-hypnotics 
and general anaesthetics (table 1). Figure 1 shows the 
frequencies and methods of administration of all 
sedation and analgesia drugs, opioids, and sedatives-
hypnotics in the TV group by country. It shows that 
opioids were given to more than 95% of neonates in the 
TV group in Cyprus, Lithuania, and Malta and to less 
than 70% in Austria, France, Germany, Greece, Portugal, 
and Spain. Sedatives-hypnotics were given to more than 
50% of infants in the TV group in Austria, Estonia, 
Germany, and Sweden, and were not given to tracheally 
ventilated neonates in Cyprus and Malta.
Figure 2 shows the frequencies and methods of 










(Continued from previous page)
Paracetamol 326 (16%) 229 (20%) 73 (11%) 24 (9%) <0·0001
Ibuprofen 15 (1%) 14 (1%) 1 (<1%) 0 (0%) 0·0123
Local anaesthetics 8 (<1%) 7 (1%) 0 (0%) 1 (<1%) 0·13
Other drugs 2 (<1%) 2 (<1%) 0 (0%) 0 (0%) 0·64
Neuromuscular blockers 259 (13%) 259 (23%) 0 (0%) 0 (0%) <0·0001
Pain assessment with a scale‡‡ 1136 (55%) 682 (60%) 342 (51%) 112 (44%) <0·0001
Withdrawal syndrome diagnosed 15 (1%) 13 (1%) 2 (<1%) 0 (0%) 0·49
Some variables had some missing values. NICU=neonatal intensive care unit. NA=not applicable. CRIB=Clinical Risk Index for Babies.*Comparisons of the three types of 
ventilation were with χ² (Fisher’s exact test when required), ANOVA, or Kruskal-Wallis test. †16 infants were intubated immediately on arrival in the unit and thus were 
included in this group. ‡Data gathering was stopped on day 28 of hospital stay; 848 (41%) of 2064 neonates were hospitalised for longer than 28 days. §For the tracheal 
ventilation group, time on non-invasive ventilation or spontaneous ventilation refers to non-invasive ventilation or spontaneous ventilation before tracheal intubation or 
after extubation; and for the non-invasive ventilation group, time on spontaneous ventilation refers to the periods of spontaneous ventilation before or after non-invasive 
ventilation. ¶Continuous or bolus, or both. ||χ² for comparison of methods of administration among the three ventilation groups. **Some neonates were given more than 
one type of analgesic or sedative. ††Of 851 neonates, 821 (96%) were given one or more of the following drugs: morphine (n=473), fentanyl (n=344), or sufentanil (n=104). 
‡‡Information was available for 1135 neonates in the tracheal ventilation group, 665 in the non-invasive ventilation group, and 256 in the spontaneous ventilation group.
 Table 2: Baseline characteristics of 2064 neonates younger than 33 weeks and use of sedation and analgesia by ventilation group in the NICUs
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Figure 1: European and 
national frequencies of the 
use of sedation and analgesia 
(A), opioids (B), and 
sedatives-hypnotics (C) in 










































































46·7%  13·7% 21·1%  
31·8% 9·1% 45·5% 
37·8% 8·1% 46·0%  
 97·6%   
41·2%  58·8%  
42·3%  50·0%  
48·5% 11·5% 15·9%  
31·0% 3·5% 41·4%  
18·3% 13·5% 34·9%   
39·7% 21·4% 25·2%  
52·2% 34·8% 8·7%  
20·0% 80·0%   
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propofol, chloral hydrate, ketamine, and paracetamol. In 
the NIV and SV groups, paracetamol was the most 
frequently used sedative analgesic in 172 (11%) of 1496 and 
202 (7%) of 3042 infants, respectively. All the other drugs 
were used in less than 3% of infants and were administered 
mainly as boluses. In the TV group, 542 (25%) of 
2142 neonates were given neuromuscular blockers, 
including suxamethonium (205 [10%]), atracurium (115 
[5%]), and pancuronium (82 [4%]). Neuro muscular 
blockers were given exclusively as boluses to 396 (18%) 
neonates in the TV group and as continuous infusions to 
146 (7%) neonates. The median duration of infusion of 
neuromuscular blockers was 33∙9 h (IQR 13∙4–65∙9; 
range 0∙2–422∙0). In the TV group, neuromuscular 
blockers were given to 183 (23%) of 779 neonates born at 
24–29 weeks gestation, 76 (21%) of 360 neonates of 
gestational age 30–32 weeks, 95 (24%) of 389 neonates of 
gestational age 33–36 weeks, and 187 (31%) of 613 neonates 
of gestational age 37–42 weeks (p=0∙0034); data were 
missing for one neonate in the TV group. All neonates 
who were given neuromuscular blockers were also given 
O-SH-GA. Bedside assessments using a pain scale were 
recorded in 1250 (58%) of 2138, 672 (45%) of 1493, and 916 
(30%) of 3017 neonates in the TV, NIV, and SV groups, 
respectively (p<0∙0001; table 1). Of 2838 neonates who 
had a pain assessment with a scale, the Enfant Douleur 
Nouveau-Né (EDIN) scale was used in 1200 (42%) 
neonates, Comfort Behavior in 416 (15%), Neonatal Pain, 
Agitation and Sedation Scale (N-PASS) in 279 (10%), 
Comfort Scale in 213 (8%), Premature Infant Pain Proﬁ le 
(PIPP) score in 139 (5%), Neonatal Infant Pain Scale 
(NIPS) in 113 (4%), Pain Assessment Tool in 101 (4%), 
Crying, Requires oxygen for saturation of more than 95%, 
Increased vital signs, Expressions, and Sleepless (CRIES) 
scale in 45 (2%), and other scales in 636 (22%). Only one 
scale was used during an assessment; however, some 
neonates had assessments with diﬀ erent scales at diﬀ erent 
times. The references for the pain assessment scales are 
provided in the appendix.
Of 2142 neonates in the TV group, 1674 (78%) were 
treated with O-SH-GA including 1634 (76%) who were 
given opioids or midazolam, or both. 1290 (60%) 
neonates in the TV group were given continuous 
infusions of O-SH-GA. 451 (21%) neonates of 2142 were 
given sedation or analgesia solely as boluses, including 
382 (18%) who were given O-SH-GA. Only 91 (4%) 
neonates were given four boluses or more and 28 (1%) 
were given ten boluses or more. 199 (9%) neonates were 
given one bolus or two boluses of O-SH-GA only on 
the day of a tracheal intubation. The reasons for bolus 
administration were not recorded.
The 2142 neonates in the TV group accounted 
for 33 715 patient-days of observation, including 


























































































































































Figure 2: Frequencies and methods of administration of morphine, fentanyl, 
sufentanil, midazolam, propofol, chloral hydrate, ketamine, and 
paracetamol according to type of ventilation
(A) Tracheal ventilation (n=2142). (B) Non-invasive ventilation (n=1496). 
(C) Spontaneous ventilation (n=3042). Percentages were calculated with the 
total number of neonates per ventilation group. 
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with out TV (days before intubation or after extubation). 
Opioids were used continuously or as bolus, or both, 
during 7960 (63%) of 12 638 patient-days with TV and 
only during 807 (4%) of 21 077 patients-days without TV 
(p<0∙0001). Sedatives were used during 2744 patient-days 
(22%) with TV and 320 patient-days (2%) without TV 
(p<0∙0001); midazolam was used for 2196 patient-days 
(17%) and 114 patient-days (1%), respectively (p<0∙0001).
All neonates (n=6307) Tracheally ventilated neonates (n=2004)
Number Any sedation or analgesia† Opioids, sedatives-hypnotics, or 
general anaesthetics‡
Number Any sedation or analgesia† Opioids, sedatives-hypnotics, or 
general anaesthetics‡
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Sex
Male 3563 1·00 1·00 1180 1·00 1·00
Female 2744 0·86 (0·74–1·00) 0·06 0·94 (0·79–1·12) 0·49 824 0·85 (0·66–1·09) 0·21 0·82 (0·65–1·04) 0·10
Gestational age (weeks)
37–42 2604 1·00 1·00 574 1·00 1·00
33–36 1765 0·61 (0·50–0·74) <0·0001 0·76 (0·60–0·95) 0·019 372 0·58 (0·39–0·87) 0·009 0·75 (0·51–1·09) 0·13
30–32 971 0·60 (0·47–0·76) <0·0001 0·62 (0·47–0·82) 0·001 343 0·48 (0·32–0·74) 0·001 0·50 (0·34–0·73) <0·0001
24–29 967 0·47 (0·36–0·61) <0·0001 0·51 (0·39–0·67) <0·0001 715 0·59 (0·38–0·90) 0·014 0·65 (0·45–0·95) 0·025
Age at admission (h)
>168 459 1·00 1·00 172 1·00 1·00
73–168 245 0·68 (0·44–1·06) 0·09 0·88 (0·52–1·51) 0·66 46 1·04 (0·20–5·51) 0·96 1·42 (0·36–5·59) 0·62
25–72 470 0·64 (0·44–0·94) 0·022 0·85 (0·53–1·38) 0·51 88 0·65 (0·23–1·82) 0·41 0·82 (0·36–1·88) 0·65
7–24 711 0·60 (0·42–0·85) 0·004 0·78 (0·51–1·18) 0·24 213 0·50 (0·20–1·24) 0·14 0·79 (0·39–1·61) 0·52
<7 4422 0·40 (0·30–0·53) <0·0001 0·39 (0·28–0·54) <0·0001 1485 0·17 (0·08–0·38) <0·0001 0·28 (0·16–0·51) <0·0001
Intrauterine growth retardation
No 5208 1·00 1·00 1680 1·00 1·00
Yes 1099 0·83 (0·67–1·03) 0·09 0·90 (0·71–1·16) 0·42 324 0·70 (0·49–0·99) 0·044 0·80 (0·58–1·01) 0·17
Respiratory distress syndrome
No 4432 1·00 1·00 1029 1·00 1·00
Yes 1875 0·75 (0·62–0·90) 0·002 1·06 (0·87–1·30) 0·56 975 0·70 (0·52–0·95) 0·021 0·88 (0·67–1·17) 0·38
CRIB score§ 6307 1·25 (1·19–1·31) <0·0001 1·26 (1·21–1·32) <0·0001 2004 1·33 (1·25–1·42) <0·0001 1·31 (1·24–1·39) <0·0001
Apgar at 1 min¶ 6307 1·0 (1·0–1·1) 0·15 1·1 (1·0–1·1) 0·009 2004 1·0 (1·0–1·1) 0·07 1·0 (1·0–1·1) 0·25
Already intubated at admission NA NA
No 731 1·00 1·00
Yes 1273 0·18 (0·13–0·26) <0·0001 0·21 (0·15–0·28) <0·0001
Respiratory support
Spontaneous ventilation 2863 1·00 1·00 NA NA
Non-invasive ventilation 1440 2·84 (2·30–3·51) <0·0001 2·83 (2·13–3·76) <0·0001
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Patients with missing data were not included in the logistic regression models. The p values and 95% CIs were adjusted with a robust sandwich estimator. NA=not applicable. CRIB=Clinical Risk Index for 
Babies.*Analysis adjusted for centres. †Includes opioids, sedatives-hypnotics, general anaesthetics, paracetamol, ibuprofen, local anaesthetics, and other drugs. ‡Opioids, sedatives-hypnotics, or general 
anaesthetics include all opioids, ketamine, benzodiazepines, propofol, barbiturates, chloral hydrate, and other sedatives; comparison with no analgesia, sedation, or other types of analgesia. §Odds ratio per point 
increase in CRIB score. ¶Odds ratio per point increase in Apgar score; this score ranges from 0 to 10. ||Area with 95% CI (0·5=no predictive value; 1·0=perfect prediction). **An internal validation of the model was 
performed using a bootstrap approach (1000 samples).
 Table 3: Logistic regression models of factors associated with the use of any sedation or analgesia and the use of opioids, sedatives-hypnotics, or general anaesthetics in all neonates and 
tracheally ventilated neonates*
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1640 (77%) of 2142, 99 (7%) of 1496, and 105 (3%) of 
3042 neonates were given opioids or benzodiazepines 
and 641 (39%) of 1636, 30 (31%) of 97, and 43 (42%) of 
103 neonates were weaned oﬀ  these gradually in the TV, 
NIV, and SV groups, respectively (p=0∙22). A drug 
withdrawal scale was used during the study for 153 (9%) 
of 1640, 11 (11%) of 99, and 27 (26%) of 105 neonates 
treated with opioids or benzodiazepines in the TV, NIV, 
and SV groups, respectively (p<0∙0001); of note, 24 (89%) 
of 27 neonates in the SV group who had an assessment 
with a drug withdrawal scale were born to mothers who 
were addicted to drugs. The scales used for the 
assessment of withdrawal in 191 neonates were the 
Finnegan scale in 107 (56%) neonates, Lipsitz scale in 
33 (17%), Withdrawal Assessment Tool-1 in eight (4%), 
Opioid and Benzodiazepine Withdrawal Scale in seven 
(4%), and other scales in 39 (20%) neonates; the 
references for the drug withdrawal scales are provided in 
the appendix. Of neonates who were given opioids or 
benzodiazepines, 69 (4%) of 1640, four (4%) of 99, and 
21 (20%) of 105 neonates were diagnosed with a drug 
withdrawal syndrome, and 111 (7%), nine (9%), and 
24 (23%) were treated or given prophylaxis in the TV, 
NIV, and SV groups, respectively (p<0∙0001). The most 
Tracheally ventilated neonates (n=2004)
Number of 
neonates
Opioids Sedatives-hypnotics General anaesthetics
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Sex
Male 1180 1·00 1·00 1·00
Female 824 0·74 (0·60–0·93) 0·008 0·91 (0·73–1·12) 0·36 1·06 (0·75–1·50) 0·74
Gestational age (weeks)
37–42 574 1·00 1·00 1·00
33–36 372 0·91 (0·64–1·29) 0·59 0·62 (0·46–0·83) 0·001 0·68 (0·40–1·15) 0·15
30–32 343 0·55 (0·39–0·79) 0·001 0·32 (0·23–0·46) <0·0001 0·65 (0·37–1·13) 0·13
24–29 715 0·69 (0·49–0·99) 0·041 0·29 (0·21–0·40) <0·0001 0·87 (0·53–1·44) 0·60
Age at admission (h)
>168 172 1·00 1·00 1·00
73–168 46 1·33 (0·39–4·50) 0·64 0·65 (0·33–1·28) 0·21 1·21 (0·46–3·20) 0·70
25–72 88 0·68 (0·32–1·43) 0·30 0·38 (0·22–0·65) 0·0004 0·74 (0·30–1·87) 0·53
7–24 213 0·84 (0·44–1·61) 0·60 0·48 (0·31–0·74) 0·001 0·60 (0·29–1·23) 0·16
<7 1485 0·32 (0·19–0·55) <0·0001 0·32 (0·23–0·46) <0·0001 0·43 (0·25–0·74) 0·002
Intrauterine growth retardation
No 1680 1·00 1·00 1·00
Yes 324 0·70 (0·52–0·95) 0·021 1·23 (0·94–1·61) 0·14 1·56 (1·03–2·37) 0·035
Respiratory distress syndrome
No 1029 1·00 1·00 1·00
Yes 975 0·86 (0·67–1·12) 0·28 0·77 (0·60–0·98) 0·04 0·77 (0·51–1·17) 0·22
CRIB score† 2004 1·31 (1·24–1·37) <0·0001 1·13 (1·10–1·17) <0·0001 1·03 (0·98–1·09) 0·22
Apgar at 1 min‡ 2004 1·04 (0·99–1·08) 0·09 1·04 (0·99–1·08) 0·09 0·98 (0·91–1·05) 0·60
Already intubated at admission
No 731 1·00 1·00 1·00
Yes 1273 0·35 (0·27–0·46) <0·0001 0·83 (0·66–1·04) 0·11 0·30 (0·20–0·44) <0·0001
Pain assessment with a scale
No 848 1·00 1·00 1·00
Yes 1156 1·73 (1·39–2·16) <0·0001 1·80 (1·45–2·23) <0·0001 2·63 (1·76–3·92) <0·0001
Model area under the receiver 
operating characteristic curve§
0·753 (0·729–0·777) 0·731 (0·706–0·755) 0·741 (0·701–0·780)
Optimism in apparent 
performance¶
–0·0000247 –0·0003018 0·0004471
Optimism-corrected area¶ 0·753 (0·729–0·777) 0·730 (0·706–0·755) 0·741 (0·701–0·781)
Patients with missing data were not included in the logistic regression models. The p values and 95% CIs were adjusted with a robust sandwich estimator. CRIB=Clinical Risk 
Index for Babies. *Analysis adjusted for centres. †Odds ratio per point increase in CRIB score. ‡Odds ratio per point increase in Apgar score; this score ranges from 0 to 10. 
§Area with 95% CI (0·5=no predictive value; 1·0=perfect prediction). ¶An internal validation of the model was done with a bootstrap approach (1000 samples).
 Table 4: Logistic regression models of factors associated with the use of opioids, sedatives-hypnotics, and general anaesthetics in tracheally ventilated 
neonates*
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common medications used to treat or prevent a drug 
withdrawal syndrome were morphine in 84 (58%), 
clonidine in 37 (26%), phenobarbital in 14 (10%), 
methadone in ten (7%), lorazepam in ﬁ ve (3%), diazepam 
in four (3%), and other drugs in 26 (18%) of 144 neonates.
The use of sedation or analgesia varied from 0% to 
100% between NICUs. Bootstrap internal validation of 
the models indicated very little optimism bias, which is 
the diﬀ erence between the model area under the receiver 
operator curve and the area we get if we sample new 
values 1000 times (diﬀ erence <0∙0005 for all models; 
tables 3 and 4). Thus, the optimism-corrected receiver 
operating characteristic (ROC) curves were almost the 
same as the original ROC curves (tables 3 and 4). 
Contributing factors for the increased use of sedation or 
analgesia in all neonates were ventilation status, 
increased CRIB scores, and bedside pain assessments, 
whereas preterm birth and younger age at NICU 
admission (<72 h) resulted in a decreased use of sedation 
or analgesia (table 3). In the TV group, use of O-SH-GA 






p value Number of 
neonates
β (SD) p value
Sex 0·17 0·13
Male 1260 118·99 (166·62) 1180 1·00
Female 880 109·00 (159·87) 824 –9·84 (6·49)
Gestational age (weeks) <0·0001
37–42 613 76·76 (106·77) 574 1·00
33–36 389 81·10 (115·34) 372 17·50 (9·94) 0·08
30–32 360 60·53 (99·67) 343 18·01 (10·84) 0·10
24–29 779 187·63 (213·62) 715 100·80 (9·76) <0·0001
Age at admission (h) 0·013
>168 224 141·75 (178·97) 172 1·00
73–168 59 143·35 (164·62) 46 19·03 (23·74) 0·42
25–72 99 80·13 (115·31) 88 –11·91 (19·24) 0·54
7–24 231 117·50 (150·35) 213 9·60 (15·19) 0·53
<7 1529 112·02 (166·15) 1485 –11·29 (12·16) 0·35
Born in same hospital as NICU 0·81 ··
No 682 116·37 (150·87) ··
Yes 1460 114·53 (170·15) ··
CRIB score 2057 0·307† <0·0001 2004 6·79 (1·08) <0·0001
Apgar at 1 min‡ 2088 –0·139† <0·0001 2004 –2·62 (1·26) 0·037
Intrauterine growth retardation 0·001 0·007
No 1785 109·73 (157·70) 1680 1·00
Yes 351 141·94 (191·04) 324 23·74 (8·79)
Respiratory distress syndrome 0·001 0·34
No 1125 103·85 (147·60) 1029 1·00
Yes 1017 127·57 (180·09) 975 7·56 (7·89)
Already intubated at admission <0·0001 <0·0001
No 766 78·72 (109·89) 731 1·00
Yes 1376 135·37 (184·73) 1273 42·22 (7·64)
Use of opioids, sedatives-hypnotics or 
general anaesthetics§
<0·0001 <0·0001
No 468 39·79 (94·71) 445 1·00
Yes 1674 136·17 (173·14) 1559 96·47 (8·36)
Pain assessment with a scale 0·002 0·0005
No 888 101·95 (159·86) 848 1·00
Yes 1250 123·85 (166·09) 1156 28·36 (8·11)
Patients with missing data were not included in the multivariable linear model. The p values and 95% CIs were adjusted with a robust sandwich estimator. CRIB=Clinical Risk 
Index for Babies. *Also adjusted for countries. †Pearson correlation with duration of tracheal ventilation. ‡Apgar score ranges from 0 to 10. §Opioids, sedatives-hypnotics, 
or general anaesthetics include all opioids, ketamine, benzodiazepines, propofol, barbiturates, chloral hydrate, and other sedatives.
 Table 5: Univariate analysis and multivariable linear model of factors associated with increased duration of tracheal ventilation
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was attributable to increased CRIB scores and bedside 
pain assessments, whereas very preterm birth (<33 weeks 
of gestation), younger age (<7 h), and being already 
intubated at NICU admission diminished use of 
O-SH-GA (table 3).
In the univariate analysis, TV in neonates treated or not 
treated with O-SH-GA lasted for a mean of 136∙2 h 
(SD 173∙1) and 39∙8 h (94∙7), respectively (p<0∙0001; 
table 5). A multivariable linear regression model adjusted 
for country, age at admission, sex, gestational age, 
intubation status at admission, CRIB and Apgar scores, 
intrauterine growth retardation, respiratory distress 
syndrome, and bedside pain assessments showed that 
use of O-SH-GA was still associated with an increased 
duration of TV (table 5).
Using the variables in table 3, propensity scores were 
calculated for 2004 (94%), including 1559 (78%) who 
were given O-SH-GA and 445 (22%) who were not, of 
2142 infants in the TV group. Propensity score matching 
yielded 427 pairs of infants who were or were not given 
O-SH-GA and eliminated previous diﬀ erences in 
covariates (ﬁ gure 3 and appendix), but showed 
substantial increases in the duration of TV associated 
with the use of O-SH-GA (mean 149∙0 h [SD 183∙6] vs 
38∙2 h [88∙5]; median 77∙3 h [IQR 25∙5–169∙8; range 
0∙5–669∙0] vs 12∙5 h [5∙8–28∙9; 0∙1–658∙4]; p<0∙0001). 
In the propensity score quintiles, use of O-SH-GA was 
associated with signiﬁ cantly increased duration of TV 
within each stratum (appendix). Two additional 
multivariable linear regression models (one including 
propensity score and O-SH-GA treatment status as 
independent variables and another including these 
variables plus all variables associated with duration of 
TV in the univariate analyses) also showed that the use 
of O-SH-GA was associated with increased duration of 
TV (data not shown). Furthermore, because in practice 
the use of these drugs might be a consequence of long 
TV, we identiﬁ ed neonates in the 427 matched pairs in 
whom the start of continuous infusion of O-SH-GA was 
within 6 h of the start of TV. We found 228 such pairs 
and again although the diﬀ erences were not signiﬁ cant 
in baseline and clinical characteristics between the 
groups with and without O-SH-GA treatment, the 
duration of TV was longer in neonates who were given 
these drugs than in those not given the drugs. In the 
228 matched pairs of neonates, the mean duration of TV 
for those given and not given O-SH-GA was 128∙1 h 
(SD 162∙4) and 40∙1 h (93∙9), respectively. These results 
were consistent with the inverse approach analysis with 
the number of ventilator-free days. In the 427 matched 
pairs, the median number of ventilation-free days for 
neonates treated with and without O-SH-GA was 22 days 
(IQR 9–26) and 26 days (25–27), respectively (p<0∙0001).
Discussion
In our study, 34% of admissions to NICUs and 82% of 
neonates who were tracheally ventilated were given some 
sedation or analgesia (table 1). In the TV group, 74% of 
neonates were given opioids and a quarter were given 
midazolam, although wide variations existed between 
centres and countries in the frequency and type of 
neonatal sedation or analgesia (ﬁ gure 1; appendix). The 
use of sedation or analgesia varied from 0% to 100% 
between centres. Our study cohort was representative of 
NICU populations in Europe with the participation of 
18 European countries, and probably of other developed 
countries, uniformity of data gathering, and more than 
90% inclusion rates in 16 countries.
Sedation or analgesia practices in the NICU 
population were previously documented in two 
declarative national surveys15,16 and one cross-sectional 
survey.17 Swedish NICUs reported using pharma-
cological analgesia during mechanical ventilation but 
not information about the type or frequency of drugs 
used;15 33 (37%) of 90 Italian NICUs reported routine 
use of opioids for mechanical ventilation.16 The results 
of a survey done in 1993–94 in 14 Canadian NICUs 
showed that 51 (21%) of 239 neonates received analgesia 
or anaesthesia, or both, during 1 week.17 In a prospective 
study of 217 patients (aged >28 days to 18 years) given 
neuromuscular blockers in PICUs, 70% were given 
sedatives and 72% opioids.18 In another prospective 
study, 338 critically ill children were treated with 
24 diﬀ erent sedatives and analgesics in 20 PICUs in the 
Figure 3: Reduction by propensity score pair matching of covariate imbalance in infants given opioids, 
sedatives-hypnotics, or general anaesthetics compared with those who were not
The sizes of the dots indicate the magnitude of the standardised diﬀ erence between groups for each variable 
before and after propensity score matching (appendix). Red lines to the right and left of zero indicate the 
positive and negative 0·1 (10%) standardised diﬀ erence limits between infants treated and not treated with 
opioids, sedatives-hypnotics, or general anaesthetics; standardised diﬀ erences of up to 10% were judged to be 
inconsequential. For example, the standardised diﬀ erence in CRIB score between the groups treated and not 
treated with opioids, sedatives-hypnotics, or general anaesthetics before matching was nearly 0·5 (50%), 
whereas the corresponding standardised diﬀ erence in the propensity-score matched pairs was 0·1 (10%). 
CRIB=Clinical Risk Index for Babies.
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UK;19 the study population included 39 neonates and 
90% of these were given morphine and 36% midazolam. 
In adults, according to a review of 20 surveys,20 reported 
from 1999 to 2009, only two surveys were prospective—
one was a national survey21 designed to study sedation 
and analgesia in ventilated adults and another was an 
international survey22 designed to study mechanical 
ventilation but not analgesia and sedation. From 2010 to 
2015, we found 15 surveys, including only two national 
prospective studies, one from Canada23 and another 
from Chile,24 of sedation and analgesia practices in 
ICUs for adults. One study25 in the USA was a 
retrospective assessment of a single-centre cohort and 
the other 12 studies (appendix) used declarative 
questionnaires mainly about the use of written local 
procedures, sedation, analgesia, sedation scales, and the 
routes of drug administration. Overall, very little was 
known about actual practice of sedation analgesia use in 
NICUs before this study. Also very little is known about 
these practices in the ICUs for adults and in PICUs.
In view of the knowledge gained over the past 
30 years that neonates can feel pain1 and evidence that 
all neonates have a consciousness,26 a humane 
approach that includes prevention or treatment of 
pain in neonates is an ethical obligation.27 This 
approach is further substantiated by associations 
between increased pain exposure and adverse 
developmental outcomes.5,28,29 Although guide lines for 
procedural pain management in neonates exist,30,31 
there are none for prolonged sedation and analgesia in 
the NICU, perhaps explaining the diﬀ erences in 
clinical practices.
In our study, 26% of all neonates and 74% of neonates 
in the TV group were given opioids (table 1). 60% of 
neonates in the TV group were given continuous 
infusions of O-SH-GA. Although, we did not record the 
exact reasons for administration of these drugs, 
continuous infusions were likely given with the purpose 
of providing sedation or analgesia during TV. Surgery, 
which was a potential reason for the use of O-SH-GA, was 
reported in only 5% of neonates in the TV group. 
Although this percentage seems low, it is likely that many 
NICUs did not have a neonatal surgical team in the same 
hospital and thus transferred neonates to surgical units in 
other hospitals. We did not gather information on this 
organisational aspect. Also likely is that O-SH-GA 
administered exclusively as boluses was given mainly for 
invasive procedures and less for sedation and analgesia 
during TV; only 4% and 1% of neonates in the TV group 
were given at least four boluses and at least ten boluses, 
respectively. Notably, 63% of neonates of all gestational 
ages and 71% of those younger than 33 weeks of gestation 
in the TV group were already intubated at admission to 
the NICU. This ﬁ nding is consistent with tracheal 
intubation being both a marker of illness severity and a 
common reason for admission to the NICU. With the 
high rate of infants born in the same hospital as the 
NICU, most of these tracheal intubations were likely done 
in the delivery room. Since we did not gather data on 
medications used before admission to the NICU, we did 
not record whether any sedation or analgesia was used for 
tracheal intubation, any other procedure, or mechanical 
ventilation before admission to the NICU. Although this 
information would have been useful, the aim in our study 
was to ascertain sedation and analgesia practices in the 
NICU; furthermore, we felt that the gathering of data by 
staﬀ  who did not participate in the study reduced the 
reliability of the data. We do not know whether the 
medications that were used for sedation and analgesia in 
neonates before admission to the NICU had any eﬀ ects 
on our results, particularly for neonates intubated before 
admission. Nonetheless, the propensity score matching 
was used with the aim of minimising bias created by 
baseline characteristics. Discussion about opioid use in 
ventilated neonates include developmentally regulated 
pain sensitivity, clinical instability from acute pain or 
stress, unsynchronised breathing, and suboptimum 
ventilation,32 and long-term eﬀ ects on brain develop-
ment.33–36 A Cochrane review concluded that opioids 
reduce neonatal pain scores, and do not prolong 
ventilation, alter mortality or subsequent intelligence, 
motor function, or behaviour,33 but evidence for the 
routine treatment of ventilated newborn babies with 
opioids is insuﬃ  cient. Variations exist in the patterns of 
opioid use in European countries. Sufentanil, for example, 
was used mostly in France and Poland, despite sparse 
data on its use.37 Another review concluded that 
remifentanil and fentanyl are more eﬀ ective than is 
morphine for tracheal intubation.38 About a quarter of 
neonates who had TV in this study did not receive any 
opioids. This might be explained, partly, by the use of 
morphine neither improving neonatal neuro-
developmental outcomes39 nor providing adequate 
analgesia for procedural pain in preterm neonates given 
TV.40 Health providers also fear that opioid use could 
prolong the length of TV. Nonetheless, we should keep in 
mind that alleviation of neonatal pain and suﬀ ering is a 
suﬃ  cient reason to use adequate analgesics, including 
opioids, in this population. In this study, the analysis of 
matched pairs showed that 25% of tracheally ventilated 
neonates who were not given O-SH-GA were ventilated 
for more than 28∙9 h and one neonate for at least 658∙4 h. 
Overall, midazolam was by far the most common sedative 
used. It was given to 25% of neonates who had TV and its 
use varied from 0% to 73% between European countries 
(appendix), despite few clinical data to lend support for 
midazolam sedation for neonates.41,42 Dexmedetomidine, 
which is frequently used for sedation of adults in the ICU, 
was not used in our study. The results of a phase 2–3 
study have shown that dexmedetomidine is eﬀ ective for 
sedating preterm and full-term neonates and is well 
tolerated without substantial adverse eﬀ ects;43 preterm 
neonates had reduced plasma clearance and increased 
elimination half-life.
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Consistent with the results of previous studies, 
logistic regression analyses showed independent 
associations of sedation and analgesia with ventilation 
status, pain assessment,44 and severity of illness.45 
Contrary to the results of a 2010 systematic review and 
meta-analysis33 that opioid exposure did not have an 
eﬀ ect on the duration of TV in the neonate, in our study 
exposure to O-SH-GA was associated with prolonged 
ventilation in the neonates. Additional multivariable 
analyses (propensity score matching, stratiﬁ cation, and 
regression adjustment) and analyses in infants in 
whom these medications were started early after 
initiation of TV substantiated this ﬁ nding, consistent 
with the ﬁ ndings from randomised trials of drug-
related respiratory depression in neonates.45–47 
Propensity score matching allowed the elimination of 
diﬀ erences in baseline characteristics between infants 
who received O-SH-GA and those who did not. Potential 
confounders such as being on TV at NICU admission 
were balanced with this approach. Before matching, 
59% of infants who were given O-SH-GA and 80% who 
were not given O-SH-GA were already intubated at 
admission (p<0∙0001; appendix); after matching, these 
frequencies were 77% and 79% (p=0∙325; appendix). 
Illness severity, as assessed with the CRIB score, was 
not diﬀ erent after matching (appendix). Also, because 
the use of O-SH-GA could be a consequence of 
prolonged TV and not its cause, we conﬁ rmed our 
ﬁ ndings in a subgroup of matched pairs in whom the 
start of continuous infusion of these drugs was within 
6 h of the initiation of TV. Neonatal brains are deﬁ cient 
in P-glycoprotein, which is needed for active extrusion 
of sedatives and analgesics from the brain,48 thus 
increasing their respiratory depressant eﬀ ects. Delayed 
excretion of these drugs, particularly in preterm 
neonates,49 might also lead to respiratory depression. 
Furthermore, after initiating O-SH-GA in tracheally 
ventilated neonates, some clinicians might not 
discontinue this treatment until the newborn baby is 
ready for extubation or is extubated.50 25% of neonates 
in the TV group were given O-SH-GA for more than 
5–7 days (appendix), increasing the risk of tolerance, 
withdrawal syndromes, and iatrogenic injury.51 Little 
information exists about other drug classes, although 
their eﬀ ects on neonatal respiratory drive might be 
similar to opioids. Use of non-pharmacological 
treatments or analgesics without respiratory depressant 
eﬀ ects for pain or stress could avoid respiratory 
depression in neonates.52
The frequencies of pain assessments were 58%, 45%, 
and 30% in the TV, NIV, and SV groups, respectively 
(table 1). These data are worrying because pain assessment 
should be standard of care in all neonates. Surprisingly, 
units that administered O-SH-GA often did not do 
accompanying pain assessments. However, neonatal pain 
assessment is not an easy task and the existence of several 
scales can be confusing.53 More research is needed on the 
implementation of pain scales at the bedside and on the 
ways of optimising pain management with pain 
assessments in neonates. Opioids or benzodiazepines 
were weaned gradually in 39%, 31%, and 42% of neonates 
in the TV, NIV, and SV groups, respectively. This practice 
is consistent with current recommendations. According 
to the American Academy of Pediatrics (AAP), each 
clinical unit should establish a threshold of cumulative 
exposure to opioids and benzodiazepines above which 
drug dependency can be expected to occur with a 
likelihood that justiﬁ es anticipatory initiation of a 
weaning protocol. For example, setting a threshold at a 
cumulative fentanyl exposure of more than 2 mg/kg or 
for longer than 7 days would predict a likelihood of 
dependency of more than 50% but less than 100%.54 
Infants with a cumulative exposure to opioids or 
benzodiazepines below the thresholds for initiation of 
weaning protocols can have a rapid taper of these 
medications over 24–48 h; those above the thresholds 
might need longer weaning of up to 2–3 weeks.54 The 
AAP also recommends that signs of drug withdrawal be 
scored with a validated abstinence assessment scale. 
Infants with conﬁ rmed drug exposure who are unaﬀ ected 
or showing minimum signs of withdrawal do not need 
medications. Although diﬀ erent medications were used 
to treat or prevent drug withdrawal syndromes in this 
study, morphine was used most commonly. The little 
available evidence from controlled trials of neonatal 
opioid withdrawal lends support for the use of oral 
morphine solution and methadone when pharmacological 
treatment is indicated; increasing evidence suggests that 
oral clonidine is also eﬀ ective either as a primary or 
adjunctive treatment, but further prospective trials are 
warranted.54
Interpretation of our results must be tempered by the 
limitations. First, the participation of eligible units 
varied widely between countries and might not 
represent each country’s practices. In most countries, 
however, several large NICUs providing advanced 
neonatal intensive care participated and allowed us to 
sample a mean of about 0∙15% births (appendix). 
Second, we cannot exclude a Hawthorne eﬀ ect (ie, a 
reaction in which individuals modify or improve their 
behaviour in response to their awareness of being 
observed), with altered bedside practices during study 
enrolment. However, data gathering for 24 h per day for 
28 days might have minimised this tendency. Third, as 
a trade-oﬀ  between study design and protocol 
compliance, we did not record the doses of medications 
used for sedation and analgesia in neonates. Requiring 
these data would have created massive burdens on the 
NICU staﬀ , lowering our participation rate in each 
country, or protocol compliance within each NICU, or 
increasing the rates of missing or incomplete data. For 
the same reasons, we did not record the purposes for 
the use of sedation and analgesia. Thus, we did not 
record how often these medications were used for 
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mechanical ventilation or for invasive procedures. The 
epidemiology of invasive procedures in the NICU has 
already been reported.55 Fourth, our models of the 
factors associated with the use of sedation and analgesia 
might be subject to bias because neonates were 
classiﬁ ed on the basis of ever or never use of sedation 
and analgesia. This dichotomy gives neonates who 
were given occasional sedation and analgesia the same 
weighting as those who were given frequent and 
longlasting sedation and analgesia. Last, we cannot 
exclude a potential bias in the association noted 
between the use of O-SH-GA and longer duration of 
tracheal ventilation using the propensity score 
approach. Although propensity score techniques can 
balance baseline covariates between exposure groups, 
they cannot balance unmeasured characteristics or 
unknown confounders. We could postulate that illness 
severity, not measured by the CRIB score, remains a 
potential confounder. Thus, as with all observational 
studies, propensity score analyses have the limitation 
that remaining unmeasured confounding might still be 
present.
Our ﬁ ndings emphasise the need to develop 
international guidelines for the judicious use of sedation 
and analgesia in the NICU, to investigate the therapeutic 
and adverse eﬀ ects of these drugs in neonates, and to 
develop new, safe approaches for sedation and analgesia 
in neonates.
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